Recombinant Activated Factor VII (rFVIIa): Characterization, Manufacturing, and Clinical Development

ABSTRACT Recombinant activated coagulation factor VII (rFVIIa) (NovoSeven®) was developed for treatment of bleeding in hemophilia patients with inhibitors (antibodies) against factors VIII or IX. rFVIIa initiates the coagulation cascade by binding to tissue factor at the site of injury and causes th...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Seminars in thrombosis and hemostasis 2001, Vol.27 (4), p.373-384
Hauptverfasser:	Jurlander, Birgit, Thim, Lars, Klausen, Niels K., Persson, Egon, Kjalke, Marianne, Rexen, Per, Jørgensen, Tom B., Østergaard, Per B., Erhardtsen, Elisabeth, Bjørn, Søren E.
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Clinical Trials as Topic Cloning, Molecular Factor VII - chemistry Factor VII - pharmacology Factor VII - therapeutic use Factor VIIa Humans Industrial Microbiology - methods Molecular Structure Recombinant Proteins - chemistry Recombinant Proteins - pharmacology Recombinant Proteins - therapeutic use Transformation, Genetic
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!